MedTrace Logo

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

NCT05768945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 742670

Last updated 2025-11-10

Study results available
· View outcomes & findings →

Summary

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Conditions

Interventions

DRUG

Semaglutide

Semaglutide claim is used as the exposure group.

DRUG

DPP-4 inhibitor

DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) claim is used as the reference group.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Rutgers University

    collaborator OTHER

  • Johns Hopkins University

    collaborator OTHER

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Madhav Thambisetty, MD, PhD · National Institute on Aging (NIA)

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-30
Primary Completion
2023-07-07
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05768945 on ClinicalTrials.gov